Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-04-26 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2020年年度报告
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2020 年年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2020 Annual Report Full Text." It contains detailed sections including company overview, financial data, business summary, risk factors, governance, and audited financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial figures, management discussion, and detailed business operations, consistent with a full annual report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2020
2021-04-26 Chinese
北京双鹭药业股份有限公司2020年度董事会工作报告
Annual Report Classification · 95% confidence The document is titled '2020 年度董事会工作报告' which translates to '2020 Annual Board of Directors Work Report'. It details the activities and meetings of the board of directors throughout the year 2020, including approvals of various reports such as the annual report, quarterly reports, internal control evaluation, social responsibility report, and audit firm appointment. It also provides a detailed overview of the company's business operations, product lines, and financial performance for the year 2020. The content is a comprehensive report on the board's work and company status for the full fiscal year 2020, which aligns with the characteristics of an Annual Report (10-K) rather than just a board announcement or a meeting summary. The length and detail confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2020
2021-04-26 Chinese
北京双鹭药业股份有限公司关于举行2020年年度报告网上业绩说明会的通知
Investor Presentation Classification · 90% confidence The document is a notice about holding an online performance explanation meeting for the 2020 annual results. It invites investors to participate in a webcast and submit questions in advance. The document does not contain actual financial data or detailed financial analysis but is an announcement about an upcoming event related to the annual report. The document length is short (702 characters), and it serves as a notification rather than the report itself or a transcript. Therefore, it fits the category of Investor Presentation (IP) or possibly AGM Information (AGM-R). However, since it is specifically about an annual performance explanation meeting (a webcast presentation), the best fit is Investor Presentation (IP).
2021-04-26 Chinese
北京双鹭药业股份有限公司公司章程修正案
Governance Information Classification · 95% confidence The document is titled '公司章程修正案' which translates to 'Amendment to the Articles of Association'. It details specific changes to the company's articles of association, including provisions about company address, share repurchase conditions, share transfer restrictions, external guarantees, and shareholder voting rights. The document is a formal announcement of these amendments and states that the changes will be submitted to the shareholders' meeting for approval. It does not contain financial statements, audit opinions, or detailed financial data. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is a regulatory announcement about governance changes, specifically amendments to the company's articles of association, which falls under Governance Information (CGR). The document length (8127 characters) is sufficient to be the actual amendment text, not just a brief announcement. Therefore, the classification is Governance Information (CGR).
2021-04-26 Chinese
北京双鹭药业股份有限公司拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Da Hua CPA Firm) as the company's auditor for the 2021 fiscal year. It details the firm's qualifications, independence, audit fees, and the approval process by the board and audit committee. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (3090 characters) and serves as a formal announcement of the intention to reappoint the auditor, which will be submitted to the shareholders for approval. Therefore, it is not an audit report itself but an announcement related to audit services. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about auditor appointment rather than the audit report or annual report itself.
2021-04-26 Chinese
2021年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021年第一季度报告正文" which translates to "2021 First Quarter Report". It contains detailed financial data including revenue, net profit, earnings per share, asset values, shareholder information, and other financial metrics for the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (12,999 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.